Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Respiratory Research

Table 5 Significantly modified proteins in post treated budesonide versus pre treated budesonide asthmatics

Swiss Prot Acc. No.	Symbol	Entrez Gene Name	Fold Change	Location	Protein Class
P01023	A2M	alpha-2-macroglobulin	-1.27	Extracellular space	cytokine
P04075	ALDOA	aldolase A, fructose-bisphosphate	-1.22	Cytoplasm	aldolase
P06576	ATP5B	ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide	-1.76	Cytoplasm	ATP synthase
Q9BPU6	DPYSL5	dihydropyrimidinase-like 5	2.01	Cytoplasm	hydrolase
P60866	RPS20	ribosomal protein S20	1.54	Cytoplasm	ribosomal protein
P29508	SERPINB3	serpin peptidase inhibitor, clade B (ovalbumin), member 3	2.31	Extracellular space	serine protease inhibitor
P08670	VIM	vimentin	-1.69	Cytoplasm	structural protein

All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student's t-test. The fold change for each protein is calculated by dividing the average ratio of the budesonide post treated biopsy with the average ratio of the paired pre budesonide biopsy. The negative fold change indicates down regulation of protein expression after budesonide treatment, while the positive fold change indicates up regulation after budesonide treatment. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.

ISSN: 1465-993X